Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy

BACKGROUND: Cancer vaccines are able to achieve tumor-specific immune editing in early-phase clinical trials. However, the infiltration of cytotoxic T cells into immune-deserted tumors is still a major limiting factor. An optimized vaccine approach to induce antigen-specific T cells that can perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiaoyi, Wang, Jian, Zheng, Xichen, Liu, Zhida, Zhang, Xinyu, Li, Yuwei, Wilhelm, Jonathan, Cao, Jun, Huang, Gang, Zhang, Jinlan, Sumer, Baran, Lea, Jayanthi, Lu, Zhigang, Gao, Jinming, Luo, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150169/
https://www.ncbi.nlm.nih.gov/pubmed/35623658
http://dx.doi.org/10.1136/jitc-2021-003960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150169/
https://www.ncbi.nlm.nih.gov/pubmed/35623658
http://dx.doi.org/10.1136/jitc-2021-003960

Ejemplares similares